Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3999660 | Urologic Oncology: Seminars and Original Investigations | 2015 | 8 Pages |
Abstract
UBPGLs typically present with a noradrenergic phenotype and are frequently associated with underlying germline mutations. Patients presenting with these rare neuroendocrine tumors should be screened for these mutations. In addition, patients with UBPGLs should be followed up closely for metastatic development regardless of genetic background, as almost half of the patients in this series presented with metastatic disease and less than half of them had SDHB mutations.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Victoria L. Martucci, Zarina G. M.D., Michael M.D., Jaydira M.D., Alexander M.D., Maria M.D., Minhaj M.D., Brian M.D., Srinivas M.D., W. Marston M.D., Piyush K. M.D., Karel M.D., Ph.D., D.Sc.,